John A Chabot, MD

Pancreas & Hepatobiliary Surgery
Cancer Care, General Surgery
More specialties
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Profile Navigation

Overview

Dr. Chabot has spent the duration of his career at NewYork-Presbyterian/Columbia since 1983, when he began his internship in transplantation. He has dedicated his career with resolute focus on the prevention, treatment, and cure for pancreatic cancer. Having progressed from intern, resident, and fellow to Professor, mentor, and Executive Director of the Pancreas Center at NewYork-Presbyterian/Columbia, Dr. Chabot intimately understands the culture and practice of medicine and surgery at the hospital. He is in a well-grounded position to lead ColumbiaDoctors in responding to the challenges associated with rapid innovation, advancing technology, and the highly informed patient.

In addition to serving as Executive Director of the Pancreas Center, Dr. Chabot is Chief of GI/Endocrine Surgery at NewYork-Presbyterian Hospital and the David V. Habif Professor of Surgery at Columbia University College of Physicians and Surgeons.

Areas of Expertise / Conditions Treated

  • Gastrointestinal Cancer
  • Hepatobiliary Pancreas Disease
  • Laparoscopic Cholecystectomy
  • Liver Cancer
  • Liver Resection Surgery
  • Pancreas Cancer
  • Pancreatic Cancer
  • Pancreatic Disease
  • Pancreatic Surgery
  • Sarcoma

Academic Appointments

  • David V. Habif Professor of Surgery at CUMC

Administrative Titles

  • Vice President, ColumbiaDoctors
  • Chief, Division of GI/Endocrine Surgery
  • Executive Director, Pancreas Center

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Male

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:
(212) 305-9468

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
Suite 819
New York, NY 10032
Primary
Phone:
(212) 305-9468
Fax:
(212) 305-5992
Open location in Google Maps
CUIMC/Milstein Hospital Building
177 Ft. Washington Avenue
New York, NY 10032
Open location in Google Maps

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • NYP Employee Plan
  • NY Signature
  • Student Health

AgeWell

  • Medicare Managed Care
  • Special Needs

Cigna

  • Great West (National)

Emblem/HIP

  • EPO
  • HMO
  • POS
  • PPO

Healthfirst

  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Quality Health Management

  • Quality Health Management

UnitedHealthcare

  • HMO
  • Oxford Freedom
  • Oxford HMO
  • Oxford Liberty
  • POS
  • PPO

World Trade Center Health Plan

  • World Trade Center Health Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • Dartmouth Medical School, NH
  • Internship: Columbia Presbyterian Medical Center, NY
  • Residency: Columbia Presbyterian Medical Center, NY
  • Fellowship: Dartmouth-Hitchcock Medical Center, NH

Committees, Societies, Councils

  • Society of Surgical Oncology
  • American Association of Endocrine Surgeons
  • American College of Surgeons, Fellow
  • American Hepato-Pancreato-Biliary Association
  • American Medical Association
  • New York Surgical Society
  • New York Transplantation Society

Board Certifications

  • Surgery

Honors & Awards

  • 2015-2016, New York Magazine's Top Doctors
  • 2015, Jerry Gliklich Practitioner of the Year Award, Society of Practitioners of CUMC
  • 2014, Teaching Award in Surgery for Excellence in Teaching and Mentoring, General Surgery Chief Residents, NYP/Columbia
  • 2008, Physician of the Year, Nursing Service of NewYork-Presbyterian Hospital
  • 2004, Special Recognition Award, NewYork-Presbyterian Hospital
  • 1998, Thomas C. King Resident Teaching Award
  • 1997, Teacher of the Year, P&S Graduating Class
  • 1991, Habif Scholar
  • 1990, Ortho Foundation Award
  • 1990, Blakemore Award for Surgical Research
  • 1987, 88-Blakemore Prize for Surgical Research
  • 1987, Upjohn Young Scientist Award
  • 1985-1987, Irvington House Institute Fellowship
  • 1979, Alpha Omega Alpha, Dartmouth Medical School
  • 1979, Signa XI, Scientific Research Society
  • 1978, Tau Beta Pi, National Engineering Honor Society
  • 1978, Magna Cum Laude, Tufts University
America's Top Doctor
NY Top Doctor

Research

Research Interests

  • Pancreatic cancer
  • Peritoneal mesothelioma

Selected Publications

  1. Chabot JA, Wei- Yann T, Fine RL, Chen C, Kumar CK, Antman KA, Grann VR.Pancreatic Proteolytic Enzyme Therapy Compared to Gemcitabine based Chemotherapy For the Treatment of Pancreatic Cancer ( Pancam) J Clin Oncol. 2010; 28 (12):2058-63.
  2. DiNorcia J, Lee MK, Reavey PL, Genkinger JM, Lee JA, Schrope BA, Chabot JA, Allendorf JD. One Hundred Thirty Resections for Pancreatic Neuroendocrine Tumor: Evaluating the Impact of Minimally Invasive and Parenchyma-Sparing Techniques. J Gastrointestinal Surgery. 2010;14(10):1536-1546.
  3. Li, Jia, Merl, Man Yee, Chabot, John A, Saif, Muhammad Wasif. Updates of Adjuvant Therapy in Pancreatic Cancer: Where Are We and Where Are We Going? Journal of the Pancreas. 2010;11(4): 310-312.
  4. Botwinick, IC, Schrope, BA, Chabot, JA. Distal Pancreatectomy with En Bloc Celiac Axis Resection After Neoadjuvant Therapy for Locally Advanced Pancreatic Adenocarcinoma. Pancreas. 2010; 39(7):1111-1113.
  5. DiNorcia J, Schrope BA, Lee MK, Reavey PL, Rosen SJ, Lee JA, Chabot JA, Allendorf JD, Laparoscopic Distal Pancreatectomy Offers Shorter Hospital Stays with Fewer Complications. J Gastrointestinal Surgery. 2010 June 30.(epub ahead of print)
  6. Kluger M, Taub RN, Hesdorffer M, Jin Z, Chabot JA. Two- Stage Operative Cytoreduction and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Operative Morbidity and Mortality in Phase I and II Trails. Eur J Surg Oncol. 2010; Jul 29.(epub ahead of print).
  7. Lee MK, DiNorcia J, Pursell LJ, Holden MM, Tsai WY, Stevens PD, Goetz N, Grann VR, Chabot JA, Allendorf JD. Prophylactic Pancreatectomy for Intraductal Papillary Mucinous Neoplasm Does Not Negatively Impact Quality of Life: A Preliminary Study. J Gastrointestinal Surgery. 23 August 2010(epub ahead of print)
  8. Lee, MK, DiNorcia J, Reavey PL, Holden MM, Genkinger JM, Lee James JA, Schrope BA, Chabot JA, Allendorf John D. Pancreaticoduodenectomy can be Performed Safely in Patients Aged 80 years and Older. J Gastrointestinal Surgery. 2010 Sept 8(Epub ahead of print).
  9. DiNorcia J, Lee MK, Reavey PL, Genkinger JM, Lee JA, Schrope BA, Chabot JA, Allendorf JD. One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg. 2010 Oct;14(10):1536-46
  10. Botwinick IC, Schrope BA, Chabot JA. Distal pancreatectomy with en bloc celiac axis resectionafter neoadjuvant therapy for locally advanced pancreatic adenocarcinoma. Pancreas. 2010 Oct;39(7):1111-3.
  11. Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010 Oct 15;16(20):5028-37.
  12. DiNorcia J, Ahmed L, Lee MK, Reavey PL, Yakaitis EA, Lee JA, Schrope BA, Chabot JA, Allendorf JD. Better preservation of endocrine function after central versus distalpancreatectomy for mid-gland lesions.Surgery. 2010 Dec;148(6):1247-54; discussion 1254-6.
  13. Saif MW, Chabot J. Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard? Nat Rev Clin Oncol. 2011 Jul 5;8(8):452-3.
  14. Sharma C, Horowitz D, Chabot J, Saif MW. Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul 8;12(4):343-6. Review.
  15. Kim R, Chabot J, Saif MW. Adjuvant treatment for ampullary cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul 8;12(4):362-3. Review.
  16. Botwinick IC, Shonkwiler RJ, Steele J, Yu G, Chabot JA. Atrial fibrillation and delayed gastric emptying. PLoS One. 2011;6(10):e25499.
  17. Roy R, Kouniavsky G, Schneider E, Allendorf JD, Chabot JA, Logerfo P, Dackiw AP, Colombani P, Zeiger MA, Lee JA. Predictive factors of malignancy in pediatric thyroid nodules. Surgery. 2011 Dec;150(6):1228-33.
  18. Goff SL, Chabot JA. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer. Cancer J. 2012 Nov-Dec;18(6):602-8.
  19. Gawlas I, Sethi M, Winner M, Epelboym I, Lee JL, Schrope BA, Chabot JA, Allendorf JD. Readmission after pancreatic resection is not an appropriate measure of quality. Ann Surg Oncol. 2013; 20(6):1781-7.
  20. Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70.
  21. Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN. Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy. Ann Surg Oncol. 2013 Apr;20(4):1101-4.
  22. Oberstein PE, Hershman DL, Khanna LG, Chabot JA, Insel BJ, Neugut AI. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study. Cancer Invest. 2013 Jun;31(5):316-22.
  23. Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, Devoe C, Chabot JA, Szabolcs M, Ludwig T, Chung WK, Frucht H. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res. 2013 Jul 1;19(13):3396-403.
  24. Leinwand JC, Zhao B, Guo X, Krishnamoorthy S, Qi J, Graziano JH, Slavkovic VN, Bates GE, Lewin SN, Allendorf JD, Chabot JA, Schwartz LH, Taub RN. Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S553-9.
  25. Winner M, Epelboym I, Remotti H, Lee JL, Schrope BA, Chabot, JA, Allendorf, JD. Predictors of recurrence in intraductal papillary mucinous neoplasm: experience with 183 pancreatic resections. J Gasstrointest Surg. 2013; 17(9):1618-26
  26. Gawlas I, Epelboym I, Winner M, DiNorcia J, Woo Y, Lee JL, Schrope BA, Chabot JA, Allendorf JD. Short-term but not long-term loss of patency of venous reconstruction during pancreatic resection is associated with decreased survival. J Gastrointest Surg. 2014 Jan;18(1):75-82.
  27. Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, Su GH. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2013 Dec 15;19(24):6830-41.
  28. Mui LW, Pursell LJ, Botwinick IC, Allendorf JD, Chabot JA, Newhouse JH. Routine intraoperative hepatic sonography does not affect staging or postsurgical hepatic recurrence in pancreatic adenocarcinoma. J Ultrasound Med. 2014 Jan;33(1):47-51
  29. Epelboym I, Winner M, DiNorcia J, Lee MK, Lee JA, Schrope B, Chabot JA, Allendorf JD. Quality of life in patients after total pancreatectomy is comparable with quality of life in patients who undergo a partial pancreatic resection. J Surg Res. 2014 Mar;187(1):189-96.
  30. Epelboym I, Digesu CS, Johnston MG, Chabot JA, Inabnet WB, Allendorf JD, Lee JA. Expanding the indications for laparoscopic retroperitoneal adrenalectomy: experience with 81 resections. J Surg Res. 2014 Apr;187(2):496-501.
  31. Epelboym I, DiNorcia J, Winner M, Lee MK, Lee JA, Schrope BA, Chabot JA, Allendorf JD. Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer. World J Surg. 2014 May;38(5):1184-95.
  32. Epelboym I, Gawlas I, Lee JA, Schrope B, Chabot JA, Allendorf JD. Limitations of ACS-NSQIP in reporting complications for patients undergoing pancreatectomy: underscoring the need for a pancreas-specific module. World J Surg. 2014 Jun;38(6):1461-7.
  33. Kuo JH, Lee JA, Chabot JA. Nonfunctional pancreatic neuroendocrine tumors. Surg Clin North Am. 2014 Jun;94(3):689-708.
  34. Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014 Jul 1;120(13):1960-7.
  35. Einersen P, Epelboym I, Winner MD, Leung D, Chabot JA, Allendorf JD. Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma. Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma.
  36. Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014 Jul 1;120(13):1960-7.
  37. Botwinick IC, Pursell L, Yu G, Cooper T, Mann JJ, Chabot JA. A biological basis for depression in pancreatic cancer. HPB (Oxford). 2014 Aug;16(8):740-3.
  38. Hassid BG, Lucas AL, Salomao M, Weng C, Liu F, Khanna LG, Kumar S, Hwang C, Chabot JA, Frucht H. Absence of pancreatic intraepithelial neoplasia predicts poor survival after resection of pancreatic cancer. Pancreas. 2014 Oct;43(7):1073-7.
  39. Kuo JH, Pasieka JL, Parrack KM, Chabot JA, Lee JA. Endocrine surgery in present-day academia. Surgery. 2014 Dec;156 (6):1461-69; discussion 1469-70.
  40. Winner M, Goff SL, Chabot JA. Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma. Semin Oncol. 2015 Feb;42(1):86-97.
  41. Afaneh C, Gerszberg D, Slattery E, Seres DS, Chabot JA, Kluger MD. Pancreatic cancer surgery and nutrition management: a review of the current literature. Hepatobiliary Surg Nutr. 2015 Feb;4(1):59-71.
  42. Sherman WH, Chu K, Chabot J, Allendorf J, Schrope BA, Hecht E, Jin B, Leung D, Remotti H, Addeo G, Postolov I, Tsai W, Fine RL. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer. 2015 Mar 1;121(5):673-80.